REG - RTW Biotech Opp. - Jade Biosciences merges with Aerovate Therapeutics

RTW Biotech OpportunitiesAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250430:nRSd6865Ga&default-theme=true

RNS Number : 6865G  RTW Biotech Opportunities Ltd  30 April 2025

LEI: 549300Q7EXQQH6KF7Z84

30 April 2025

RTW Biotech Opportunities Ltd

Jade Biosciences merges with Aerovate Therapeutics

 

RTW Biotech Opportunities Ltd (the "Company"), the London Stock
Exchange-listed investment company focused on identifying transformative
assets with high growth potential across the life sciences sector, is pleased
to note the announcement by one of its portfolio companies, Jade Biosciences
("Jade"), of the closing of its merger with Aerovate Therapeutics
("Aerovate"). The combined company will operate as "Jade Biosciences, Inc."
and will trade on Nasdaq under the ticker symbol "JBIO".

 

Jade is a private biotechnology company focused on developing potentially
best-in-class therapies for autoimmune diseases. Lead candidate JADE-001 is on
track to enter the clinic in the second half of 2025, with initial data
expected in the first half of 2026. JADE-001 is an investigational anti-A
PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of
Immunoglobulin A nephropathy (IgAN), an autoimmune condition that damages the
kidneys and potentially progresses to end-stage kidney disease requiring
dialysis or transplantation.

 

The Company first invested in Jade's seed round in August 2024. As at 31 March
2025, Jade represented 0.6% of NAV.

 

Rod Wong, CIO of RTW Investments, said, "The merger of Jade and Aerovate
demonstrates that compelling portfolio activity continues despite elevated
market volatility. Jade Biosciences will be well positioned to advance
JADE-001 into clinical trials this year, making meaningful progress to combat
autoimmune diseases."

 

 

The full text of the announcement can be read at  https://jadebiosciences.com
(https://jadebiosciences.com/press-release/jade-biosciences-completes-closing-of-merger-with-aerovate-therapeutics-and-previously-announced-private-placement-of-approximately-300-million/)
.

 

Enquiries:

 RTW Investments, LP - Investment Manager               +44 (0)20 7959 6361

 Woody Stileman (Business Development)                  biotechopportunities@rtwfunds.com

 Oliver Kenyon (Business & Corporate Development)

 Krisha McCune (Investor Relations)

 Cadarn Capital - PR & IR Partner

 Lucy Clark (PR)                                        +44 (0)7984 184 461 / lucy@cadarncapital.com

 David Harris (Distribution)                            +44 (0)7368 883 211 / david@cadarncapital.com

 Deutsche Numis - Joint Corporate Broker                +44 (0)20 7260 1000

 Freddie Barnfield

 Nathan Brown

 Euan Brown

 BofA Securities - Joint Corporate Broker               +44 (0)20 7628 1000

 Edward Peel

 Alex Penney

 Altum (Guernsey) Limited                               +44 (0)1481 703 100

 Joanna Duquemin Nicolle

 Sadie Morrison

 

 

 

About RTW Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on
identifying transformative assets with high growth potential across the
biopharmaceutical and medical technology sectors. Driven by a long-term
approach to support innovative businesses, RTW Biotech Opportunities Ltd
invests in companies developing next-generation therapies and technologies
that can significantly improve patients' lives. RTW Biotech Opportunities Ltd
is managed by RTW Investments, LP, a leading healthcare-focused
entrepreneurial investment firm with deep scientific expertise and a strong
track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd
(https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/)  for more
information.

 

***********

The information in this announcement may include forward-looking statements,
which are based on the current expectations and projections about future
events, and in certain cases can be identified by the use of terms such as
"may", "will", "should", "expect", "anticipate", "project", "estimate",
"intend", "continue", "target", "believe" (or the negatives thereon) or other
variations thereon or comparable terminology. These forward-looking
statements, as well as those included in any related materials, are subject to
risks, uncertainties and assumptions about the Company and/or its underlying
investments, including, among other things, the development of the applicable
entity's business, trends in its operating industry, expected use of financing
proceeds and future capital expenditures and acquisitions. In light of these
risks, uncertainties and assumptions, the events in the forward-looking
statements may not occur.

The information contained in this announcement is given at the date of its
publication (unless otherwise marked). No reliance may be placed for any
purpose whatsoever on the information or opinions contained in this
announcement or on its completeness, accuracy or fairness.

***********

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDBUGDSSSDDGUC